GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
presented by
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
GW Pharmaceuticals gets first FDA approval for CBD-based drug
The FDA approved the cannabis-based drug for treating seizures in two severe forms of epilepsy.